Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: A Southwest oncology group trial

Charles W. Taylor, Michael LeBlanc, Richard I. Fisher, Dennis F. Moore, Ralph W. Roach, Laurence Elias, Thomas P Miller

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

We performed a phase II, Southwest Oncology Group (SWOG) clinical trial of recombinant human interleukin-4 (rhuIL-4) in patients with previously treated non-Hodgkin's lymphoma (NHL). We studied 18 eligible patients with lowgrade and 21 patients with intermediate- or high-grade NHL. All patients had received prior chemotherapy. A protocol amendment after the first four patients reduced the frequency of s.c. rhulL-4 administration from daily to 3 times per week at 3 μg/kg and limited the number of prior chemotherapy regimens allowed. We documented no complete or partial responses in the low-grade NHL group [0%; 95% confidence interval (Cl) 0-19%]. One patient in the inter-mediate/high-grade NHL group developed a partial response lasting longer than 15 months (5%; 95% Cl 0-24%). Median survivals for the low- and intermediate/high-grade NHL groups were 15 and 13 months, respectively. Common toxicities included: arhralgia/myalgia, fatigue/malaise/ lethargy, fever, headache, nausea and rigors/chills. Cardiac toxicity, gastrointestinal ulceration and nasal congestion due to rhulL-4 were not prominent toxicities in our patients. Our previously treated NHL patients tolerated s.c. rhulL-4 at a dose of 3 <gm>g/kg given 3 times per week, but objective response rarely occurred. Further evaluation of rhulL-4 in these patient populations does not appear warranted. (C) 2000 Lippincott Williams and Wilkins.

Original languageEnglish (US)
Pages (from-to)695-700
Number of pages6
JournalAnti-Cancer Drugs
Volume11
Issue number9
DOIs
StatePublished - 2000

Fingerprint

Interleukin-4
Non-Hodgkin's Lymphoma
Drug Therapy
Chills
Lethargy
Myalgia
Nose
Nausea
Fatigue
Headache
Fever
Clinical Trials
Confidence Intervals
Survival

Keywords

  • Interleukin-4
  • Lymphoma
  • Phase II
  • SWOG

ASJC Scopus subject areas

  • Pharmacology
  • Cancer Research
  • Oncology

Cite this

Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma : A Southwest oncology group trial. / Taylor, Charles W.; LeBlanc, Michael; Fisher, Richard I.; Moore, Dennis F.; Roach, Ralph W.; Elias, Laurence; Miller, Thomas P.

In: Anti-Cancer Drugs, Vol. 11, No. 9, 2000, p. 695-700.

Research output: Contribution to journalArticle

Taylor, Charles W. ; LeBlanc, Michael ; Fisher, Richard I. ; Moore, Dennis F. ; Roach, Ralph W. ; Elias, Laurence ; Miller, Thomas P. / Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma : A Southwest oncology group trial. In: Anti-Cancer Drugs. 2000 ; Vol. 11, No. 9. pp. 695-700.
@article{68cfa4c01db44583b79ddfd80ffdba03,
title = "Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: A Southwest oncology group trial",
abstract = "We performed a phase II, Southwest Oncology Group (SWOG) clinical trial of recombinant human interleukin-4 (rhuIL-4) in patients with previously treated non-Hodgkin's lymphoma (NHL). We studied 18 eligible patients with lowgrade and 21 patients with intermediate- or high-grade NHL. All patients had received prior chemotherapy. A protocol amendment after the first four patients reduced the frequency of s.c. rhulL-4 administration from daily to 3 times per week at 3 μg/kg and limited the number of prior chemotherapy regimens allowed. We documented no complete or partial responses in the low-grade NHL group [0{\%}; 95{\%} confidence interval (Cl) 0-19{\%}]. One patient in the inter-mediate/high-grade NHL group developed a partial response lasting longer than 15 months (5{\%}; 95{\%} Cl 0-24{\%}). Median survivals for the low- and intermediate/high-grade NHL groups were 15 and 13 months, respectively. Common toxicities included: arhralgia/myalgia, fatigue/malaise/ lethargy, fever, headache, nausea and rigors/chills. Cardiac toxicity, gastrointestinal ulceration and nasal congestion due to rhulL-4 were not prominent toxicities in our patients. Our previously treated NHL patients tolerated s.c. rhulL-4 at a dose of 3 g/kg given 3 times per week, but objective response rarely occurred. Further evaluation of rhulL-4 in these patient populations does not appear warranted. (C) 2000 Lippincott Williams and Wilkins.",
keywords = "Interleukin-4, Lymphoma, Phase II, SWOG",
author = "Taylor, {Charles W.} and Michael LeBlanc and Fisher, {Richard I.} and Moore, {Dennis F.} and Roach, {Ralph W.} and Laurence Elias and Miller, {Thomas P}",
year = "2000",
doi = "10.1097/00001813-200010000-00004",
language = "English (US)",
volume = "11",
pages = "695--700",
journal = "Anti-Cancer Drugs",
issn = "0959-4973",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma

T2 - A Southwest oncology group trial

AU - Taylor, Charles W.

AU - LeBlanc, Michael

AU - Fisher, Richard I.

AU - Moore, Dennis F.

AU - Roach, Ralph W.

AU - Elias, Laurence

AU - Miller, Thomas P

PY - 2000

Y1 - 2000

N2 - We performed a phase II, Southwest Oncology Group (SWOG) clinical trial of recombinant human interleukin-4 (rhuIL-4) in patients with previously treated non-Hodgkin's lymphoma (NHL). We studied 18 eligible patients with lowgrade and 21 patients with intermediate- or high-grade NHL. All patients had received prior chemotherapy. A protocol amendment after the first four patients reduced the frequency of s.c. rhulL-4 administration from daily to 3 times per week at 3 μg/kg and limited the number of prior chemotherapy regimens allowed. We documented no complete or partial responses in the low-grade NHL group [0%; 95% confidence interval (Cl) 0-19%]. One patient in the inter-mediate/high-grade NHL group developed a partial response lasting longer than 15 months (5%; 95% Cl 0-24%). Median survivals for the low- and intermediate/high-grade NHL groups were 15 and 13 months, respectively. Common toxicities included: arhralgia/myalgia, fatigue/malaise/ lethargy, fever, headache, nausea and rigors/chills. Cardiac toxicity, gastrointestinal ulceration and nasal congestion due to rhulL-4 were not prominent toxicities in our patients. Our previously treated NHL patients tolerated s.c. rhulL-4 at a dose of 3 g/kg given 3 times per week, but objective response rarely occurred. Further evaluation of rhulL-4 in these patient populations does not appear warranted. (C) 2000 Lippincott Williams and Wilkins.

AB - We performed a phase II, Southwest Oncology Group (SWOG) clinical trial of recombinant human interleukin-4 (rhuIL-4) in patients with previously treated non-Hodgkin's lymphoma (NHL). We studied 18 eligible patients with lowgrade and 21 patients with intermediate- or high-grade NHL. All patients had received prior chemotherapy. A protocol amendment after the first four patients reduced the frequency of s.c. rhulL-4 administration from daily to 3 times per week at 3 μg/kg and limited the number of prior chemotherapy regimens allowed. We documented no complete or partial responses in the low-grade NHL group [0%; 95% confidence interval (Cl) 0-19%]. One patient in the inter-mediate/high-grade NHL group developed a partial response lasting longer than 15 months (5%; 95% Cl 0-24%). Median survivals for the low- and intermediate/high-grade NHL groups were 15 and 13 months, respectively. Common toxicities included: arhralgia/myalgia, fatigue/malaise/ lethargy, fever, headache, nausea and rigors/chills. Cardiac toxicity, gastrointestinal ulceration and nasal congestion due to rhulL-4 were not prominent toxicities in our patients. Our previously treated NHL patients tolerated s.c. rhulL-4 at a dose of 3 g/kg given 3 times per week, but objective response rarely occurred. Further evaluation of rhulL-4 in these patient populations does not appear warranted. (C) 2000 Lippincott Williams and Wilkins.

KW - Interleukin-4

KW - Lymphoma

KW - Phase II

KW - SWOG

UR - http://www.scopus.com/inward/record.url?scp=0033664461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033664461&partnerID=8YFLogxK

U2 - 10.1097/00001813-200010000-00004

DO - 10.1097/00001813-200010000-00004

M3 - Article

C2 - 11129730

AN - SCOPUS:0033664461

VL - 11

SP - 695

EP - 700

JO - Anti-Cancer Drugs

JF - Anti-Cancer Drugs

SN - 0959-4973

IS - 9

ER -